|
Characteristics of HBsAg-positive patients with hepatic dysfunction and without hepatic dysfunction during chemotherapy |
|||
| Patients with hepatic dysfunction (No = 40) (49.4%) |
Patients without hepatic dysfunction (No = 41) (50.6%) |
p-value |
|
|
|
|||
| Sex |
0.22 |
||
| Male |
23(57.5) |
18(43.9) |
|
| Female |
17(42.5) |
23(56.1) |
|
| Age (years) |
0.096 |
||
| ≤ 60 |
28(70) |
35(85.4) |
|
| > 60 |
12(30) |
6(14.6) |
|
| Staging |
0.088 |
||
| I/II |
13(32.5) |
21(51.2) |
|
| III/IV |
27(67.5) |
20(48.8) |
|
| B symptom |
0.43 |
||
| Positive |
15(37.5) |
12(29.3) |
|
| Negative |
25(62.5) |
29(70.7) |
|
| PS |
0.41 |
||
| 0,1 |
38(95) |
37(90.2) |
|
| 2,3,4 |
2(5) |
4(9.8) |
|
| LDH |
0.75 |
||
| ≤ Normal value |
22(55) |
24(58.5) |
|
| > Normal value |
18(45) |
17(41.5) |
|
| Extranodal sites |
0.42 |
||
| 0–1 |
34(85) |
32(78) |
|
| > 1 |
6(15) |
9(22) |
|
| Liver involvement |
0.63 |
||
| Yes |
7(17.5) |
5(12.2) |
|
| No |
33(82.5) |
36(87.8) |
|
| Spleen involvement |
0.50 |
||
| Yes |
12(30) |
11(26.8) |
|
| No |
28(70) |
30(73.2) |
|
| HBV status prior to CT |
0.38 |
||
| HBsAg(+), HBeAg(+), Anti-HBc(+) |
11(27.5) |
15(36.6) |
|
| HBsAg(+), Anti-HBe(+), Anti-HBc(+) |
29(72.5) |
26(63.4) |
|
| Liver dysfunction prior to CT |
0.38 |
||
| Yes |
10(25) |
7(17.1) |
|
| No |
30(75) |
34(82.9) |
|
| Radiation |
0.037 |
||
| Yes |
8(20) |
17(41.5) |
|
| No |
32(80) |
24(58.5) |
|
| Chemotherapy |
0.90 |
||
| No. Range |
2–20 |
1–13 |
|
| Median |
6 |
6 |
|
| Response to front-line chemotherapy |
0.26 |
||
| CR |
18(45) |
25(61) |
|
| PR |
19(47.5) |
12(29.3) |
|
| SD |
1(2.5) |
3(7.3) |
|
| PD |
2(5) |
1(2.4) |
|
Wang et al. BMC Cancer 2008 8:115 doi:10.1186/1471-2407-8-115 |
|||